Navigation Links
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Date:9/21/2007

ngoing study, the company anticipates filing an NDA for TREANDA in patients with indolent NHL who are refractory to rituximab in the fourth quarter of 2007. In addition, Cephalon is studying TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. The company anticipates that results from studies of TREANDA as monotherapy and in combination will be presented at medical meetings later this year.

Upon FDA acceptance of the company's NDA filing of TREANDA for CLL, the company will make a $15 million milestone payment to former shareholders of Salmedix.

About TREANDA

TREANDA is a rationally designed purine analog/alkylator hybrid. Preclinical data demonstrate that TREANDA induces rapid, sustained single- and double-strand DNA damage, which results in apoptosis, or programmed cell death, in the tumor. TREANDA also induces mitotic checkpoint inhibition, which results in non-apoptotic cell death. TREANDA causes DNA disruption that is both extensive and durable exhibiting a low level of cross-resistance to other cytotoxic agents. The dual-effect of the anti-tumor activity of TREANDA may be attributable to its unique chemical design.

Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from Astellas Deutschland GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation Limited, under the tradename RIBOMUSTIN(R). In Germany, RIBOMUSTIN is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to market and sell bendamustine HCl in Asia.

About Cephalon Oncology

Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. Highest Possible Transformation Efficiencies for High-Throughput Applications
3. Unique DNA Polymerase Formulation Excels in a Broad Range of PCR Applications
4. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
5. An Assessment of the Eppendorf twin.tec plate performance in PCR* applications
6. Principles and applications of electrical cell fusion
7. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
8. Optimizing Büchi® Rotary Evaporator Applications
9. Principles and applications of electrical cell fusion
10. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
11. Optimizing Büchi® Rotary Evaporator Applications

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... November 5, 2009 Senomy...ng proprietary taste receptor-based technologies t...beverage, and ingredient supply industries, today ... results for the third quarter ended September 30,...uarter of 2009, compared to $4.0 million for the t...
(Date:11/5/2009)... Drug safety specialty firm BioSoteria announ...matics earned the Certified Professional in Learni...he American Society for Training and Development (...as more than fifteen years of medical communicatio...onsible for the development of the company,s onlin...
(Date:11/4/2009)... The Human Anthrax Vaccine Program must be st... feature film "A Call to Arms:2009 Edition&qu...Fatal Immunity: The Human Anthrax Vaccine Story&qu...nt danger of top secret government science turned ...ountability to its victims. It is available for w...
(Date:11/4/2009)...lif., Nov. 4 Onyx Pharma...hat it will present at the Credit Suisse 18th Annu..., at 9:30 a.m. Mountain Time (8:30 a.m. Pacific Ti... of the presentation on our website at: http://w..., It is recommended that listeners log on 15 minu...
Breaking Biology Technology:SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7
...nc. (Nasdaq: DCTH ), a medical technology compa...rfusion ("PHP") System for the treatment of cancer...ty percent (46 of 92) of patients have been enroll...atic cutaneous and ocular melanoma to the liver. ...ial continue to evaluate and enroll patients and t...
.../ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ON...eeded the primary statistical endpoint in its mult...travenous administration of REOLYSIN(R) in patient...the lung. , "The proportion of patients on study...responses is highly encouraging," said Dr. Frank G...
... announced today,that it has agreed with Pfizer to...edients (API) site in Ireland. This site manufactu...l ingredient. , The site has had a number of..., then Hickson & Welch, Warner Lambert, Pfizer...s invested several hundred million dollars in,plan...
Other Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 4Hovione Buys Pfizer's Loughbeg API Facility 2Hovione Buys Pfizer's Loughbeg API Facility 3
(Date:11/6/2009)...TROIT, Nov. 6 Auburn Hills, MI-bas... will be installing its locker system and patent-p...at the U.S. Department of Health and Human Service...thesda, MD. The locker system will support the NI...otecting our nation,s medical research agency. Th...
(Date:11/4/2009)...ELPHIA Although scientists are reluctant to offic...hod, evidence continues to grow about its protecti...shed in Cancer Prevention Research , a journal of...ch suggests some reduction in oral cancer. , Va...icine in the Department of Thoracic/Head and Neck ...
(Date:11/4/2009)...ngapore laboratory that deciphered the DNA codes, ...elephant shark, has joined The Genome 10K Project,...pository of DNA sequences on 10,000 species of ani... that currently can not be achieved. , Participa...er published in the Nov. 5, 2009 issue of the Jou...
Breaking Biology News(10 mins):Does green tea prevent cancer? Evidence continues to brew, but questions remain 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Adam 26 Eves Great American Sex Survey Asks How Was YOUR First Time 3F 57838 1Adam 26 Eves Great American Sex Survey Asks How Was YOUR First Time 3F 57838 2Veterans Healing Initiative Formed to Help Meet Burgeoning Addiction and Mental Health Issues of Returning U S Veterans 57835 1Veterans Healing Initiative Formed to Help Meet Burgeoning Addiction and Mental Health Issues of Returning U S Veterans 57835 2Perrigo Company To Host Investor Day 57833 1
...xpected to exacerbate drought events throughout th...tion and failure of drought-sensitive crops. In a... in severity and length, making it difficult for p...dern varieties of potatoes are considered to be dr...on in the cold, dry Andean Altiplano gave rise to ...
...toes can be up to 1000 times larger than their wil..., domesticated food plants have larger fruits, hea...he characteristics that early hunter-gatherers cho...omatoes have been bred for shape, texture, flavor,...been difficult to study these traits in tomatoes, ...
...vailable in French and Spanish . , Montreal, ...re joining forces to protect and conserve the Mona...America,s shared environment. , Although the mona...r of extinction, its unique multigenerational migr...ngered biological phenomenon due to threats to the...
Other Biology News:Drought tolerance in potatoes 2Drought tolerance in potatoes 3Evolution of fruit size in tomato 2Evolution of fruit size in tomato 3Continental plan to protect the monarch's migratory journey 2
Rabbit Anti-KIAA1276 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Cytokeratin 5 / 14 Monoclonal Antibody, Unconjugated, Clone LH8 from Abcam
Rabbit Anti-IL-23 P19 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human C1QC Polyclonal Antibody, Unconjugated from Atlas Antibodies
Biology Products: